AdvisorNet Financial Inc lowered its stake in Sanofi (NASDAQ:SNY – Get Rating) by 22.5% in the second quarter, HoldingsChannel.com reports. The firm owned 1,641 shares of the company’s stock after selling 477 shares during the quarter. AdvisorNet Financial Inc’s holdings in Sanofi were worth $82,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also modified their holdings of SNY. GHP Investment Advisors Inc. acquired a new stake in Sanofi during the 1st quarter worth $26,000. Fairfield Bush & CO. acquired a new position in shares of Sanofi during the 1st quarter worth about $26,000. Pinnacle Bancorp Inc. increased its stake in shares of Sanofi by 49.0% during the 1st quarter. Pinnacle Bancorp Inc. now owns 587 shares of the company’s stock worth $30,000 after purchasing an additional 193 shares during the last quarter. Ahrens Investment Partners LLC acquired a new position in shares of Sanofi during the 1st quarter worth about $31,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Sanofi during the 1st quarter worth about $32,000. Institutional investors and hedge funds own 10.33% of the company’s stock.
Sanofi Price Performance
Shares of NASDAQ:SNY opened at $39.13 on Friday. The firm’s 50 day moving average price is $43.81 and its 200-day moving average price is $48.70. The stock has a market capitalization of $99.19 billion, a PE ratio of 13.00, a price-to-earnings-growth ratio of 1.01 and a beta of 0.53. Sanofi has a twelve month low of $38.66 and a twelve month high of $58.10. The company has a quick ratio of 0.34, a current ratio of 1.29 and a debt-to-equity ratio of 0.22.
Analyst Upgrades and Downgrades
A number of brokerages recently commented on SNY. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Sanofi from €90.00 ($91.84) to €85.00 ($86.73) and set a “hold” rating on the stock in a research note on Wednesday, September 7th. Cheuvreux cut shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Wednesday, August 24th. UBS Group cut shares of Sanofi from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 9th. Credit Suisse Group increased their price objective on shares of Sanofi from €105.00 ($107.14) to €110.00 ($112.24) and gave the stock an “outperform” rating in a research report on Friday, July 22nd. Finally, Morgan Stanley cut their target price on shares of Sanofi from €112.00 ($114.29) to €93.00 ($94.90) in a research note on Thursday, September 8th. Four equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Sanofi has an average rating of “Moderate Buy” and an average price target of $105.38.
Sanofi Company Profile
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.
- Get a free copy of the StockNews.com research report on Sanofi (SNY)
- What Steelcase’s Earnings Say About the Return to the Office?
- The Institutions Hold On To Darden Restaurants International
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.